578 related articles for article (PubMed ID: 33052750)
1. Monoclonal antibodies as an addition to current myeloma therapy strategies.
Jullien M; Touzeau C; Moreau P
Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
[TBL] [Abstract][Full Text] [Related]
2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
4. CD38 as an immunotherapeutic target in multiple myeloma.
Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
[TBL] [Abstract][Full Text] [Related]
5. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
6. Current antibody-based therapies for the treatment of multiple myeloma.
Varga C; Waldschmidt JM; Gandolfi S; Richardson PG
Clin Adv Hematol Oncol; 2020 Nov; 18(11):736-748. PubMed ID: 33406065
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
De Luca F; Allegra A; Di Chio C; Previti S; ZappalĂ M; Ettari R
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi UH; Cornell RF; Lakshman A; Gahvari ZJ; McGehee E; Jagosky MH; Gupta R; Varnado W; Fiala MA; Chhabra S; Malek E; Mansour J; Paul B; Barnstead A; Kodali S; Neppalli A; Liedtke M; Narayana S; Godby KN; Kang Y; Kansagra A; Umyarova E; Scott EC; Hari P; Vij R; Usmani SZ; Callander NS; Kumar SK; Costa LJ
Leukemia; 2019 Sep; 33(9):2266-2275. PubMed ID: 30858549
[TBL] [Abstract][Full Text] [Related]
12. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
Abramson HN
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707894
[TBL] [Abstract][Full Text] [Related]
13. Antibody treatment in multiple myeloma.
Maples KT; Johnson C; Lonial S
Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT; Ye JC
J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
[TBL] [Abstract][Full Text] [Related]
15. Antibody therapies for multiple myeloma.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
Expert Opin Biol Ther; 2020 Mar; 20(3):295-303. PubMed ID: 31944131
[No Abstract] [Full Text] [Related]
16. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for the treatment of multiple myeloma.
Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
[TBL] [Abstract][Full Text] [Related]
18. Novel targets for the treatment of relapsing multiple myeloma.
Giuliani N; Accardi F; Marchica V; Dalla Palma B; Storti P; Toscani D; Vicario E; Malavasi F
Expert Rev Hematol; 2019 Jul; 12(7):481-496. PubMed ID: 31125526
[No Abstract] [Full Text] [Related]
19. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
[TBL] [Abstract][Full Text] [Related]
20. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.
Morandi F; Horenstein AL; Costa F; Giuliani N; Pistoia V; Malavasi F
Front Immunol; 2018; 9():2722. PubMed ID: 30546360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]